COVID-19

The rapid global spread and epidemiological characteristics of COVID-19 are deeply concerning. CEPI has moved quickly and urgently to coordinate with global health authorities and partners to rapidly develop vaccine candidates against the disease.

CEPI’s response to COVID-19

The spread of COVID-19 is rapidly becoming a humanitarian and economic crisis. All evidence now suggests eradication is no longer feasible and that we face a global public health crisis which is unprecedented in modern times.

CEPI has moved quickly and collaboratively to rapidly develop vaccines against the COVID-19 virus. We are also collaborating with GSK and will use their pandemic vaccine adjuvant platform technology to enhance the development of an effective vaccine.

We have issued an urgent call for US$2 billion to increase our chances of finding an effective vaccine, which can be ready for licensure or use in outbreaks. Without immediate additional investment, CEPI will not be able to continue supporting its programmes and develop a vaccine the world needs.

Invest Now

Key Milestones

{{year}}

{{item.title}}